Skip to main content
Clinical Trials/ISRCTN41236511
ISRCTN41236511
Completed
N/A

Extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomised, placebo-controlled trial

Storz Medical AG (Switzerland)0 sites20 target enrollmentDecember 20, 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
on-calcifying tendinopathy of supraspinatus tendon
Sponsor
Storz Medical AG (Switzerland)
Enrollment
20
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 20, 2010
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Storz Medical AG (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • 1\. Male and non\-pregnant female patients 18 years of age or older (women of child\-bearing potential must have a negative serum pregnancy test performed within 1 \- 14 days prior to the treatment procedure) suffering from chronic non\-calcific supraspinatus tendinopathy as diagnosed by X\-ray, magnetic resonance imaging (MRI) and physical examination
  • 2\. Patient has not responded to a standard course of non\-pharmacological and non\-surgical conservative treatment for a minimum of 4 months. Non\-surgical conservative treatment may consist of: therapeutic exercise, ultrasound, iontophoresis, cryotherapy, and immobilisation or activity modification.
  • 3\. Patient has not responded to non\-surgical, pharmacological conservative treatment and has had at least one sub\-acromial steroid injection and at least one course of the standard dose of prescribed non\-steroidal anti\-inflammatory drugs (NSAIDs) or other pharmacological therapy a minimum of thirty days prior to SV
  • 4\. Diagnosis of supraspinatus tendinopathy is only in one shoulder
  • 5\. Patient has free passive range of movement and at least 90 degrees active abduction in the affected shoulder
  • 6\. Patient is willing to participate in the study and return for all scheduled follow\-up visits
  • 7\. Patient is capable of giving, and has given, written informed consent

Exclusion Criteria

  • 1\. Patient has a history of uncontrolled severe hypertension (systolic pressure greater than 180 mmHg, diastolic pressure greater than 110 mmHg)
  • 2\. Patient has unstable or uncontrolled angina, uncontrolled heart failure, or serious uncontrolled ventricular arrhythmias
  • 3\. Patient has a white blood cell count less than 2,000 or greater than 15,000, and/or platelet count less than 50,000
  • 4\. Patient has a known bleeding disorder or is currently being treated with anticoagulant therapy
  • 5\. Patient is currently being treated with a narcotic or NSAIDs and/or has used analgesics or NSAIDs within the 72 hours prior to the SV
  • 6\. Patient has participated in any other shoulder pain treatment research study within 30 days prior to the SV
  • 7\. Patient has had prior shoulder surgery
  • 8\. Patient is complaining of pain in both shoulders
  • 9\. Patient has malignant tumours, irrespective of location
  • 10\. Patient has a cardiac pacemaker implant

Outcomes

Primary Outcomes

Not specified

Similar Trials